NCT02535689View on ClinicalTrials.gov

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 28, 2015

Primary Completion Date

April 26, 2018

Study Completion Date

April 26, 2018

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

Tofacitinib

Oral administration of tofacitinib, 5 mg

DRUG

Placebo

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

NCT02535689 - Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter